AstraZeneca forecast higher 2022 sales and lifted its annual dividend for the first time in a decade after record revenues last year, but warned the boost from its Covid-19 products would decline.
The Anglo-Swedish drugmaker said it made almost $4bn (£2.9bn) last year from the Covid jab it developed with Oxford University. It moved away from its not-for-profit pricing in November, when it signed new contracts in Latin America, the Middle East and Asia. The shot, called Vaxzevria, has not yet been approved by the US regulator.
